To Discover the Efficient and Novel Drug Targets in Human Cancers Using CRISPR/Cas Screening and Databases

被引:11
|
作者
Onishi, Iichiroh [1 ]
Yamamoto, Kouhei [1 ]
Kinowaki, Yuko [1 ]
Kitagawa, Masanobu [1 ]
Kurata, Morito [1 ]
机构
[1] Tokyo Med & Dent Univ, Grad Sch Med, Dept Comprehens Pathol, Tokyo 1138510, Japan
关键词
CRISPR screening; synthetic lethality; database; SCALE CRISPR-CAS9 KNOCKOUT; SYNTHETIC LETHAL; TRANSCRIPTIONAL ACTIVATION; CELL-DEATH; GENOME; GENES; INHIBITION; SUPPRESSOR; EXPRESSION; DRIVE;
D O I
10.3390/ijms222212322
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CRISPR/Cas has emerged as an excelle nt gene-editing technology and is used worldwide for research. The CRISPR library is an ideal tool for identifying essential genes and synthetic lethality targeted for cancer therapies in human cancers. Synthetic lethality is defined as multiple genetic abnormalities that, when present individually, do not affect function or survival, but when present together, are lethal. Recently, many CRISPR libraries are available, and the latest libraries are more accurate and can be applied to few cells. However, it is easier to efficiently search for cancer targets with their own screenings by effectively using databases of CRISPR screenings, such as Depmap portal, PICKLES (Pooled In-Vitro CRISPR Knockout Library Essentiality Screens), iCSDB, Project Score database, and CRISP-view. This review will suggest recent optimal CRISPR libraries and effective databases for Novel Approaches in the Discovery and Design of Targeted Therapies.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Highly efficient CRISPR-Cas9-mediated editing identifies novel mechanosensitive microRNA-140 targets in primary human articular chondrocytes
    Chaudhry, N.
    Muhammad, H.
    Seidl, C.
    Downes, D.
    Young, D. A.
    Hao, Y.
    Zhu, L.
    Vincent, T. L.
    OSTEOARTHRITIS AND CARTILAGE, 2022, 30 (04) : 596 - 604
  • [22] Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update
    Chaudhary, Mayank
    Sharma, Pooja
    Mukherjee, Tapan Kumar
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (12) : 11491 - 11502
  • [23] Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update
    Mayank Chaudhary
    Pooja Sharma
    Tapan Kumar Mukherjee
    Molecular Biology Reports, 2022, 49 : 11491 - 11502
  • [24] CRISPR/Cas9-mediated noncoding RNA editing in human cancers
    Yang, Jie
    Meng, Xiaodan
    Pan, Jinchang
    Jiang, Nan
    Zhou, Chengwei
    Wu, Zhenhua
    Gong, Zhaohui
    RNA BIOLOGY, 2018, 15 (01) : 35 - 43
  • [25] DOMAIN-FOCUSED CRISPR SCREENING IDENTIFIES POTENTIAL DRUG TARGETS
    不详
    CANCER DISCOVERY, 2015, 5 (07) : 693 - 693
  • [26] A human systems biology approach to discover new drug targets in epilepsy
    Loeb, Jeffery A.
    EPILEPSIA, 2010, 51 : 171 - 177
  • [27] Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery
    Roth, BL
    Lopez, E
    Beischel, S
    Westkaemper, RB
    Evans, JM
    PHARMACOLOGY & THERAPEUTICS, 2004, 102 (02) : 99 - 110
  • [28] Harnessing the Power of CRISPR/Cas9 to Discover Novel, Synthetically-Lethal FDA-Approved Drug Combinations for Gastrointestinal Malignancies
    Dogeas, E.
    Shi, G.
    Xie, Y.
    Mendell, J. T.
    Augustine, M.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S28 - S28
  • [29] A simple and efficient method for CRISPR/Cas9-induced mutant screening
    Yufeng Hua
    Chun Wang
    Jian Huang
    Kejian Wang
    Journal of Genetics and Genomics, 2017, 44 (04) : 207 - 213
  • [30] Identifying Drug Targets via Whole Exome Sequencing and CRISPR-Cas9
    Zhou, Sirui
    Laurent, Laetitia
    Kemp, John
    Pramatarova, Albena
    Forgetta, Vincenzo
    Morris, John
    Croucher, Peter
    Williams, Graham
    Bassett, Duncan
    Goltzman, David
    Lotta, Luca
    Evans, David
    Richards, Brent
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 22 - 22